微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 51.77% | 20.94% | 3.21% | 71/159 | -2.21% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 50.16% | 24.76% | 8.58% | 71/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 46.19% | 26.04% | 9.61% | 80/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 42.14% | -8.93% | -1.54% | 98/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 42.81% | -9.28% | 6.48% | 93/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 40.2% | -15.31% | 9.69% | 99/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 36.65% | -21.04% | -20.8% | 103/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.28% | 73.06% | -1.92% | 90/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 47.18% | 13.98% | -0.61% | 86/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 47.47% | -6.79% | 2.28% | 87/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 46.41% | -21.54% | 73.57% | 87/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 26.74% | -46.72% | -35.4% | 129/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 41.39% | -21.23% | -18.72% | 94/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 50.93% | -7.89% | -13.9% | 83/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 59.16% | 3.02% | 17.86% | 61/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 50.19% | -6.43% | -4.5% | 84/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 52.55% | -3.64% | -4.96% | 69/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 55.29% | 1.05% | -3.71% | 70/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 57.42% | 6.97% | 7.06% | 59/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 53.64% | -15.01% | -1.65% | 76/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 54.54% | -14.36% | -0.33% | 63/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 54.72% | -16.51% | 1.93% | 65/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 53.68% | -13.32% | -14.93% | 56/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 63.11% | -8.36% | -0.9% | 52/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 63.68% | 139.59% | -2.84% | 39/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 65.54% | 148.9% | 5.82% | 36/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 61.93% | 120.5% | -10.07% | 38/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 68.87% | 126.09% | 159.11% | 37/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 26.58% | -16.59% | 0.94% | 94/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 26.33% | -15.38% | -6.25% | 100/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 28.09% | -2.71% | -7.79% | 91/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 30.46% | 5.94% | -4.41% | 102/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 31.87% | 7.33% | 2.4% | 73/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 31.12% | 6.33% | 7.79% | 78/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 28.87% | 1.64% | 0.4% | 63/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 28.75% | -1.23% | -3.16% | 91/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 29.69% | 2% | 1.45% | 63/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 29.27% | 2% | 3.03% | 70/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 28.4% | 2% | -2.43% | 59/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 29.11% | 4.96% | 4.96% | 80/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |